We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Progranulin and CTRP3 in Metabolic Syndrome

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01668888
First Posted: August 20, 2012
Last Update Posted: August 20, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
K. M. Choi, Korea University
  Purpose
Inflammation has been known to be a pivotal pathogenic mechanism of obesity-related disorders such as type 2 diabetes, metabolic syndrome and atherosclerosis. Adipose tissue functions as a major endocrine organ by adipokine mediated modulation of a number of signaling cascades in target tissues, that has pro-inflammatory or anti-inflammatory activities. Progranulin and CTRP3 are recently discovered novel adipokines. Therefore, the investigators tried to clarify the clinical meaning of these two adipokines in the subjects with or without metabolic syndrome

Condition
Metabolic Syndrome

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional

Resource links provided by NLM:


Further study details as provided by K. M. Choi, Korea University:

Primary Outcome Measures:
  • Serum concentration of progranulin in the subjects with metabolic syndrome [ Time Frame: 12week ]
  • Serum concentration of CTRP3 in the subjects with metabolic syndrome [ Time Frame: 12week ]

Secondary Outcome Measures:
  • The relationship of serum progranulin levels with cardiovascular risk factors [ Time Frame: 12 week ]
  • The relationship of serum CTRP3 levels with cardiovascular risk factors [ Time Frame: 12 week ]

Enrollment: 127
Study Start Date: May 2012
Study Completion Date: August 2012
Primary Completion Date: August 2012 (Final data collection date for primary outcome measure)
Groups/Cohorts
Apparently Helathy Subjects

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
The subjects who visited for a routine health check-up at the Health Promotion Center of Korea University Guro Hospital were enrolled using predefined inclusion and exclusion criteria.
Criteria

Inclusion Criteria:

  • 20<age<80
  • apparently healthy subjects

Exclusion Criteria:

  • a history of CVD
  • diabetes
  • stage 2 hypertension
  • malignancy
  • severe renal or hepatic disease
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01668888


Locations
Korea, Republic of
Korea University Guro Hospital
Seoul, Korea, Republic of
Sponsors and Collaborators
Korea University
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: K. M. Choi, Professor, Korea University
ClinicalTrials.gov Identifier: NCT01668888     History of Changes
Other Study ID Numbers: KoreaHealth_Progranulin
First Submitted: August 14, 2012
First Posted: August 20, 2012
Last Update Posted: August 20, 2012
Last Verified: August 2012

Additional relevant MeSH terms:
Syndrome
Metabolic Syndrome X
Disease
Pathologic Processes
Insulin Resistance
Hyperinsulinism
Glucose Metabolism Disorders
Metabolic Diseases